Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elaine H Morrato

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Medical Care|April 29, 2017
The Case for Funding Our National Drug Safety Surveillance SystemElaine H Morrato
Journal of General Internal Medicine|July 5, 2014
Capsule commentary on Sabbatini et al., controlling health costs: physician responses to patient expectations for medical careElaine H Morrato
The Lancet. Psychiatry|April 16, 2021
Interpreting evidence on long-acting injectable antipsychoticsElaine H Morrato
Neurorehabilitation and Neural Repair|August 22, 2018
Implementation Science: Ensuring the Return on Our Research InvestmentElaine H Morrato
Pharmacoepidemiology and Drug Safety|July 6, 2006
Effectiveness of risk management plans: a case study of pemoline using pharmacy claims dataElaine H Morrato, Judy A Staffa
Medical Care|October 11, 2012
The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAAElaine H Morrato, Sarah B Ling
JAMA|September 20, 2012
FDA approval of obesity drugs: a difference in risk-benefit perceptionsElaine H Morrato, David B Allison
Therapeutics and Clinical Risk Management|March 10, 2015
Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improvedElaine H Morrato, Meredith Y Smith
Current Opinion in Pediatrics|May 14, 2008
Surgical outcomes research: a progression from performance audits, to assessment of administrative databases, to prospective risk-adjusted analysis - how far have we come?Elaine H Morrato, Peter Dillon, Moritz Ziegler
Frontiers in Public Health|March 12, 2020
Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIMGita A Toyserkani, Linda Huynh, Elaine H Morrato
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Medical Care|April 29, 2017
The Case for Funding Our National Drug Safety Surveillance SystemElaine H Morrato
Journal of General Internal Medicine|July 5, 2014
Capsule commentary on Sabbatini et al., controlling health costs: physician responses to patient expectations for medical careElaine H Morrato
The Lancet. Psychiatry|April 16, 2021
Interpreting evidence on long-acting injectable antipsychoticsElaine H Morrato
Neurorehabilitation and Neural Repair|August 22, 2018
Implementation Science: Ensuring the Return on Our Research InvestmentElaine H Morrato
Pharmacoepidemiology and Drug Safety|July 6, 2006
Effectiveness of risk management plans: a case study of pemoline using pharmacy claims dataElaine H Morrato, Judy A Staffa
Medical Care|October 11, 2012
The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAAElaine H Morrato, Sarah B Ling
JAMA|September 20, 2012
FDA approval of obesity drugs: a difference in risk-benefit perceptionsElaine H Morrato, David B Allison
Therapeutics and Clinical Risk Management|March 10, 2015
Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improvedElaine H Morrato, Meredith Y Smith
Current Opinion in Pediatrics|May 14, 2008
Surgical outcomes research: a progression from performance audits, to assessment of administrative databases, to prospective risk-adjusted analysis - how far have we come?Elaine H Morrato, Peter Dillon, Moritz Ziegler
Frontiers in Public Health|March 12, 2020
Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIMGita A Toyserkani, Linda Huynh, Elaine H Morrato
Pageof 9